Summary
In the US, compounding drugs are medications produced by compounding pharmacies, who typically make personalised versions of medications, such as custom dosages, combinations or allergen-free options. In this JAMA article, US journalist Kate Ruder looks at patient safety concerns linked to the rapid increase in demand for anti-obesity medications including semaglutide and tirzepatide. Kate highlights how high demand, ensuing scarcity, prohibitive costs and restrictive insurance coverage have fuelled the production of compounded versions of these medications under a provision allowing compounding pharmacies to make copycats during drug shortages. Concerns have been raised about the quality of ingredients, accuracy of doses and the supply of counterfeit medications by companies selling fake products, as well as about the potential for user error when they give themselves the medication.
0 Comments
Recommended Comments
There are no comments to display.
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!
Register a new accountSign in
Already have an account? Sign in here.
Sign In Now